Search Results - "Fredrick B. Hagemeister"

Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma by Strati, Paolo, Varma, Ankur, Adkins, Sherry, Nastoupil, Loretta J, Westin, Jason, Hagemeister, Fredrick B, Fowler, Nathan H, Lee, Hun J, Fayad, Luis E, Samaniego, Felipe, Ahmed, Sairah, Chen, Yiming, Horowitz, Sandra, Arafat, Sara, Johncy, Swapna, Kebriaei, Partow, Mulanovich, Victor Eduardo, Ariza Heredia, Ella, Neelapu, Sattva S

“…Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 may be associated with long-term adverse effects such as cytopenia and immune deficiency. In…”
Get full text

Double hit lymphoma: the MD Anderson Cancer Center clinical experience by Oki, Yasuhiro, Noorani, Mansoor, Lin, Pei, Davis, Richard E., Neelapu, Sattva S., Ma, Long, Ahmed, Mohamed, Rodriguez, Maria Alma, Hagemeister, Fredrick B., Fowler, Nathan, Wang, Michael, Fanale, Michelle A., Nastoupil, Loretta, Samaniego, Felipe, Lee, Hun J., Dabaja, Bouthaina S., Pinnix, Chelsea C., Medeiros, Leonard J., Nieto, Yago, Khouri, Issa, Kwak, Larry W., Turturro, Francesco, Romaguera, Jorge E., Fayad, Luis E., Westin, Jason R.

“…Summary We report our experience with 129 cases of double hit lymphoma (DHL), defined as B‐cell lymphoma with translocations and/or extra signals involving MYC…”
Get full text

Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma by Strati, Paolo, Ahmed, Mohamed Amin, Fowler, Nathan H, Nastoupil, Loretta J, Samaniego, Felipe, Fayad, Luis E, Hagemeister, Fredrick B, Romaguera, Jorge E, Rodriguez, Alma, Wang, Michael, Westin, Jason R, Cheah, Chan, Noorani, Mansoor, Feng, Lei, Davis, Richard E, Neelapu, Sattva S

“…The impact of pre-treatment maximum standardized uptake value (SUV ) on the outcome of follicular lymphoma (FL) following specific frontline regimens has not…”
Get full text

Predictors of Radiation Pneumonitis in Patients Receiving Intensity Modulated Radiation Therapy for Hodgkin and Non-Hodgkin Lymphoma by Pinnix, Chelsea C., MD, PhD, Smith, Grace L., MD, PhD, Milgrom, Sarah, MD, Osborne, Eleanor M., MD, Reddy, Jay P., MD, PhD, Akhtari, Mani, MD, Reed, Valerie, MD, Arzu, Isidora, MD, Allen, Pamela K., PhD, Wogan, Christine F., MS, Fanale, Michele A., MD, Oki, Yasuhiro, MD, Turturro, Francesco, MD, Romaguera, Jorge, MD, Fayad, Luis, MD, Fowler, Nathan, MD, Westin, Jason, MD, Nastoupil, Loretta, MD, Hagemeister, Fredrick B., MD, Rodriguez, M. Alma, MD, Ahmed, Sairah, MD, Nieto, Yago, MD, PhD, Dabaja, Bouthaina, MD

“…Purpose Few studies to date have evaluated factors associated with the development of radiation pneumonitis (RP) in patients with Hodgkin lymphoma (HL) and…”
Get full text

Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia by Wang, Yingjun, Gali, Vasantha Lakshmi, Xu-Monette, Zijun Y., Sano, Dahlia, Thomas, Sheeba K., Weber, Donna M., Zhu, Feng, Fang, Xiaosheng, Deng, Manman, Zhang, Mingzhi, Hagemeister, Fredrick B., Li, Yong, Orlowski, Robert Z., Lee, Hans Chulhee, Young, Ken H.

“…Waldenström macroglobulinemia (WM) is a distinct type of indolent lymphoplasmacytic lymphoma (LPL) with a high frequency of MYD88L265P mutation. Treatment for…”
Get full text

A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas by Strati, Paolo, Nastoupil, Loretta J, Davis, Richard E, Fayad, Luis E, Fowler, Nathan, Hagemeister, Fredrick B, Kwak, Larry, Oki, Yasuhiro, Wang, Michael, Westin, Jason, Ruben, Charnelle E, Wesson, Emily T, Piekarz, Richard, Fanale, Michelle A, Lee, Hun Ju

Get full text

CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma by Takahashi, Koichi, Sivina, Mariela, Hoellenriegel, Julia, Oki, Yasuhiro, Hagemeister, Fredrick B., Fayad, Luis, Romaguera, Jorge E., Fowler, Nathan, Fanale, Michelle A., Kwak, Larry W., Samaniego, Felipe, Neelapu, Sattva, Xiao, Lianchun, Huang, Xuelin, Kantarjian, Hagop, Keating, Michael J., Wierda, William, Fu, Kai, Chan, Wing C., Vose, Julie M., O'Brien, Susan, Davis, Richard E., Burger, Jan A.

“…Summary B cell receptor (BCR) signalling is an important pathway in diffuse large B cell lymphoma (DLBCL). In response to BCR triggering, normal and malignant…”
Get full text

Improvement of Overall and Failure-Free Survival in Stage IV Follicular Lymphoma: 25 Years of Treatment Experience at The University of Texas M.D. Anderson Cancer Center by QI LIU, FAYAD, Luis, YOUNES, Anas, PRO, Barbara, LEE, Ming-Sheng, AYALA, Ana, MCLAUGHLIN, Peter, CABANILLAS, Fernando, HAGEMEISTER, Fredrick B, AYERS, Gregory D, HESS, Mark, ROMAGUERA, Jorge, RODRIGUEZ, M. Alma, TSIMBERIDOU, Apostolia M, VERSTOVSEK, Srdan

“…Advanced-stage follicular lymphoma is considered incurable. The pace of improvements in treatment has been slow. This article analyzes five sequential cohorts…”
Get full text

Incidence and Risk Factors of Venous Thromboembolic Events in Lymphoma by Zhou, Xiao, MD, PhD, Teegala, Shyam, MD, MPH, Huen, Auris, PharmD, Ji, Yuan, PhD, Fayad, Luis, MD, Hagemeister, Fredrick B., MD, Gladish, Gregory, MD, Vadhan-Raj, Saroj, MD

“…Abstract Background Cancer patients are at increased risk of venous thromboembolism; however, the incidence and risk factors for venous thromboembolism in…”
Get full text

PD-L1 + macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma by Steiner, Raphael E, Parra, Edwin R, Vega, Francisco, Feng, Lei, Westin, Jason R, Neelapu, Sattva S, Strati, Paolo, Green, Michael R, Flowers, Christopher R, Solis, Luisa M, Wistuba, Ignacio I, Ahmed, Sairah, Nair, Ranjit, Hagemeister, Fredrick B, Noorani, Mansoor, Marques-Piubelli, Mario L

“…Primary mediastinal (thymic) large B-cell lymphoma (PMBCL) is a rare, aggressive subtype of non-Hodgkin lymphoma and has a complex inflammatory…”
Get full text

Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma by You, Hua, Xu-Monette, Zijun Y., Wei, Li, Nunns, Harry, Nagy, Máté L., Bhagat, Govind, Fang, Xiaosheng, Zhu, Feng, Visco, Carlo, Tzankov, Alexandar, Dybkaer, Karen, Chiu, April, Tam, Wayne, Zu, Youli, Hsi, Eric D., Hagemeister, Fredrick B., Huh, Jooryung, Ponzoni, Maurilio, Ferreri, Andrés J.M., Møller, Michael B., Parsons, Benjamin M., Van Krieken, J. Han, Piris, Miguel A., Winter, Jane N., Li, Yong, Au, Qingyan, Xu, Bing, Albitar, Maher, Young, Ken H.

“…Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma with high mutation burdens but a low response rate to immune checkpoint inhibitors…”
Get full text

Follicular dendritic cell sarcoma: A report of 14 cases and a review of the literature by Soriano, Andres O., Thompson, Michael A., Admirand, Joan H., Fayad, Luis E., Rodriguez, Alma M., Romaguera, Jorge E., Hagemeister, Fredrick B., Pro, Barbara

“…Follicular dendritic cell sarcomas (FDCS) are grouped with the histiocytic and dendritic cell neoplasms. The natural history and response to different…”
Get full text

Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality by Khouri, Issa F., Saliba, Rima M., Giralt, Sergio A., Lee, Ming-Sheng, Okoroji, Grace-Julia, Hagemeister, Fredrick B., Korbling, Martin, Younes, Anas, Ippoliti, Cindy, Gajewski, James L., McLaughlin, Peter, Anderlini, Paolo, Donato, Michele L., Cabanillas, Fernando F., Champlin, Richard E.

“…This study investigated the use of a nonablative conditioning regimen to decrease toxicity and achieve engraftment of an allogeneic blood stem cell transplant,…”
Get full text

Positron Emission Tomography/Computed Tomography Findings During Therapy Predict Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemotherapy Alone but Not in Those Who Receive Consolidation Radiation by Dabaja, Bouthaina S., MD, Hess, Kenneth, PhD, Shihadeh, Ferial, MD, Podoloff, Donald A., MD, Medeiros, L. Jeffrey, MD, Mawlawi, Osama, PhD, Arzu, Isidora, MD, PhD, Oki, Yasuhiro, MD, Hagemeister, Fredrick B., MD, Fayad, Luis E., MD, Reed, Valerie K., MD, Kedir, Aziza, BS, Wogan, Christine F., MS, Rodriguez, Alma, MD

“…Purpose To assess the value of mid-therapy positron emission tomography (PET) findings for predicting survival and disease progression in patients with diffuse…”
Get full text

The Absolute Monocyte and Lymphocyte Prognostic Index for Patients With Diffuse Large B-Cell Lymphoma Who Receive R-CHOP by Batty, Nicolas, Ghonimi, Elham, Feng, Lei, Fayad, Luis, Younes, Anas, Rodriguez, Maria Alma, Romaguera, Jorge Enrique, McLaughlin, Peter, Samaniego, Felipe, Kwak, Larry W, Hagemeister, Fredrick B

“…Micro-Abstract An index based on the initial absolute lymphocyte and monocyte counts may provide prognostic information regarding outcome beyond that of the…”
Get full text

Long-Term Follow-Up of a Prospective Study of Combined Modality Therapy for Stage I–II Indolent Non-Hodgkin’s Lymphoma by SEYMOUR, John F, PRO, Barbara, HESS, Mark, COX, James D, CABANILLAS, Fernando, MCLAUGHLIN, Peter, FULLER, Lillian M, MANNING, John T, HAGEMEISTER, Fredrick B, ROMAGUERA, Jorge, RODRIGUEZ, Maria A, HA, Chul S, SMITH, Terry L, AYALA, Ana

“…Standard therapy for patients with stage I-II indolent lymphoma has been involved-field radiation therapy (IF-XRT), which achieves 10-year disease-free…”
Get full text

Phase II Study of Denileukin Diftitox for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma by DANG, Nam H, HAGEMEISTER, Fredrick B, GOY, Andre, RODRIGUEZ, Maria A, WALKER, Pamela L, ARREDONDO, Yolanda, TONG, Ann T, FAYAD, Luis, PRO, Barbara, MCLAUGHLIN, Peter, ROMAGUERA, Jorge E, JONES, Dan, SAMUELS, Barry, SAMANIEGO, Felipe, YOUNES, Anas, WANG, Michael

“…Denileukin diftitox is a fusion protein combining diphtheria toxin and interleukin-2 (IL-2) that targets tumor cells expressing the IL-2 receptor. Its efficacy…”
Get full text

Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma by Jain, Preetesh, Zhao, Shuangtao, Lee, Hun Ju, Hill, Holly A, Ok, Chi Young, Kanagal-Shamanna, Rashmi, Hagemeister, Fredrick B, Fowler, Nathan, Fayad, Luis, Yao, Yixin, Liu, Yang, Moghrabi, Omar B, Navsaria, Lucy, Feng, Lei, Nogueras Gonzalez, Graciela M, Xu, Guofan, Thirumurthi, Selvi, Santos, David, Iliescu, Cezar, Tang, Guilin, Medeiros, L Jeffrey, Vega, Francisco, Avellaneda, Michelle, Badillo, Maria, Flowers, Christopher R, Wang, Linghua, Wang, Michael L

“…Most patients with mantle cell lymphoma (MCL) are older. In this study, we investigated the efficacy and safety of a chemotherapy-free combination with…”
Get full text

Impact of High-Dose Chemotherapy on Peripheral T-Cell Lymphomas by RODRIGUEZ, Jose, MUNSELL, Mark, ROMAGUERA, Jorge, CABANILLAS, Fernando F, CHAMPLIN, Richard E, KHOURI, Issa F, YAZJI, Salim, HAGEMEISTER, Fredrick B, YOUNES, Anas, ANDERSSON, Borje, GIRALT, Sergio, GAJEWSKI, James, DE LIMA, Marcos, COURIEL, Daniel

“…To evaluate the outcome of high-dose chemotherapy (HDCT) and autologous or allogeneic hematopoietic transplantation in patients with peripheral T-cell lymphoma…”
Get full text

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial by Fowler, Nathan H, Dr, Davis, R Eric, MD, Rawal, Seema, PhD, Nastoupil, Loretta, MD, Hagemeister, Fredrick B, Prof, McLaughlin, Peter, Prof, Kwak, Larry W, Prof, Romaguera, Jorge E, Prof, Fanale, Michelle A, MD, Fayad, Luis E, MD, Westin, Jason R, MD, Shah, Jatin, MD, Orlowski, Robert Z, Prof, Wang, Michael, Prof, Turturro, Francesco, Prof, Oki, Yasuhiro, MD, Claret, Linda C, RN, Feng, Lei, MS, Baladandayuthapani, Veerabhadran, PhD, Muzzafar, Tariq, MD, Tsai, Kenneth Y, MD, Samaniego, Felipe, MD, Neelapu, Sattva S, MD

“…Summary Background Standard treatments for indolent non-Hodgkin lymphomas are often toxic, and most patients ultimately relapse. Lenalidomide, an…”
Get full text